128
Views
3
CrossRef citations to date
0
Altmetric
Original Article

vwF A3-GPI modification of EPCs accelerates reendothelialization of injured vessels via collagen targeting in mice

, , , , , , & show all
Pages 744-751 | Received 03 Nov 2015, Accepted 11 Feb 2016, Published online: 17 Mar 2016

References

  • Caiado F, Dias S. Endothelial progenitor cells and integrins: adhesive needs. Fibrogenesis Tissue Repair 2012;5:4 doi:10.1186/1755-1536-5-4.
  • Moccia F, Dragoni S, Lodola F, et al. Store-dependent Ca(2+) entry in endothelial progenitor cells as a perspective tool to enhance cell-based therapy and adverse tumour vascularization. Curr Med Chem 2012;19:5802–18.
  • Napoli C, Hayashi T, Cacciatore F, et al. Endothelial progenitor cells as therapeutic agents in the microcirculation: an update. Atherosclerosis 2011;215:9–22.
  • Avci-Adali M, Ziemer G, Wendel HP. Induction of EPC homing on biofunctionalized vascular grafts for rapid in vivo self-endothelialization – a review of current strategies. Biotechnol Adv 2010;28:119–29.
  • Aburakawa Y, Kawabe J, Okada M, et al. Prostacyclin stimulated integrin-dependent angiogenic effects of endothelial progenitor cells and mediated potent circulation recovery in ischemic hind limb model. Circ J 2013;77:1053–62.
  • Huang S, Tang Y, Cai X, et al. Celastrol inhibits vasculogenesis by suppressing the VEGF-induced functional activity of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 2012;423:467–72.
  • Templin C, Kotlarz D, Marquart F, et al. Transcoronary delivery of bone marrow cells to the infarcted murine myocardium: feasibility, cellular kinetics, and improvement in cardiac function. Basic Res Cardiol 2006;101:301–10.
  • Ishikawa T, Eguchi M, Wada M, et al. Establishment of a functionally active collagen-binding vascular endothelial growth factor fusion protein in situ. Arterioscler Thromb Vasc Biol 2006;26:1998–2004.
  • Medof ME, Nagarajan S, Tykocinski ML. Cell-surface engineering with GPI-anchored proteins. FASEB J 1996;10:574–86.
  • Muenchmeier N, Boecker S, Bankel L, et al. A novel CXCL10-based GPI-anchored fusion protein as adjuvant in NK-based tumor therapy. PLoS One 2013;8:e72749.
  • Yin Y, Zhao X, Fang Y, et al. SDF-1alpha involved in mobilization and recruitment of endothelial progenitor cells after arterial injury in mice. Cardiovasc Pathol 2010;19:218–27.
  • McHugh RS, Nagarajan S, Wang YC, et al. Protein transfer of glycosyl-phosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy. Cancer Res 1999;59:2433–7.
  • Huang JH, Getty RR, Chisari FV, et al. Protein transfer of preformed MHC-peptide complexes sensitizes target cells to T cell cytolysis. Immunity 1994;1:607–13.
  • Nagarajan S, Anderson M, Ahmed SN, et al. Purification and optimization of functional reconstitution on the surface of leukemic cell lines of GPI-anchored Fc gamma receptor III. J Immunol Methods 1995;184:241–51.
  • Brodsky RA, Jane SM, Vanin EF, et al. Purified GPI-anchored CD4DAF as a receptor for HIV-mediated gene transfer. Hum Gene Ther 1994;5:1231–9.
  • Brunschwig EB, Fayen JD, Medof ME, Tykocinski ML. Protein transfer of glycosyl-phosphatidylinositol (GPI)-modified murine B7-1 and B7-2 costimulators. J Immunother 1999;22:390–400.
  • Djafarzadeh R, Mojaat A, Vicente AB, et al. Exogenously added GPI-anchored tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) displays enhanced and novel biological activities. Biol Chem 2004;385:655–63.
  • Kong D, Melo LG, Mangi AA, et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 2004;13:1769–75.
  • Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res 1993;73:792–6.
  • Werner N, Junk S, Laufs U, et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 2003;93:e17–24.
  • Stavik B, Tinholt M, Sletten M, et al. TFPIα and TFPIβ are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity. J Hematol Oncol 2013;6:5. doi:10.1186/1756-8722-6-5.
  • Liew A, Barry F, O’Brien T. Endothelial progenitor cells: diagnostic and therapeutic considerations. Bioessays 2006;28:261–70.
  • Goussetis E, Manginas A, Koutelou M, et al. Intracoronary infusion of CD133+ and CD133-CD34+ selected autologous bone marrow progenitor cells in patients with chronic ischemic cardiomyopathy: cell isolation, adherence to the infarcted area, and body distribution. Stem Cells 2006;24:2279–83.
  • Stuckey DJ, Carr CA, Martin-Rendon E, et al. Iron particles for noninvasive monitoring of bone marrow stromal cell engraftment into, and isolation of viable engrafted donor cells from, the heart. Stem Cells 2006;24:1968–75.
  • Dzau VJ, Gnecchi M, Pachori AS, et al. Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension 2005;46:7–18.
  • Aoki J, Serruys PW, van Beusekom H, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005;45:1574–9.
  • McHugh RS, Ahmed SN, Wang YC, et al. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci USA 1995;92:8059–63.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.